Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Minerva Neurosciences faces FDA challenges with roluperidone in Q4

Minerva Neurosciences' Q4 2022 earnings call highlighted challenges with FDA interactions for roluperidone, alongside financial updates. Despite hurdles, the company expressed confidence in its data package and the potential of roluperidone to meet medical needs. Ongoing FDA dialogue remains critical for addressing regulatory concerns and advancing the schizophrenia treatment.

Minerva Neurosciences advances NDA filing for roluperidone, faces regulatory challenges

Minerva Neurosciences showcased progress in drug development and financial stability while facing challenges in regulatory processes and financial uncertainties. The company's strategic focus on unique drug profiles and milestone achievements presents opportunities for growth and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024.

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?

BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024.

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences said on Tuesday the U.S. Food and Drug Administration has declined to approve its experimental drug for the treatment of negative symptoms in patients with schizophrenia.

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third quarter ended September 30, 2023.

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for schizophrenia, albeit for cognitive impairments associated with schizophrenia. NERV has six months until the PDUFA goal date for its roluperidone application but used only $4M in cash in operating activities in Q2, so cash isn't currently a concern.

Minerva Neurosciences: There's Probably Time For One More Rally

BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares of its common stock at a purchase price of $9.99 per pre-funded warrant, to Boehringer Ingelheim, a global biopharmaceutical company with a growing mental health pipeline that includes schizophrenia, and Federated Hermes Kaufmann Funds in a private investment in public equity (the “PIPE”) financing. Minerva expects that the gross proceeds from the PIPE will be approximately $20 million, before deducting PIPE-related expenses payable by Minerva. Minerva intends to use the net proceeds from the PIPE to support potential regulatory approval in the U.S., commercialization activities and market launch of roluperidone, which is being developed for the treatment of negative symptoms in schizophrenia.

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now

Ads-Tec Energy PLC

Applied Blockchain Inc

Context Therapeutics LLC

eFFECTOR Therapeutics Inc

Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.

Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners

NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal to File letter this time, with NERV using a dispute resolution process to its advantage.

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

What Makes Minerva Neurosciences (NERV) a New Buy Stock

Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Geoff Race - President Dr. Remy Luthringer - Executive Chairman and CEO Fred Ahlholm - Senior Vice President and CFO Conference Call Participants Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Operator Welcome to the Minerva Neurosciences First Quarter 2023 Conference Call.

Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript

BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter ended March 31, 2023.

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26, 2024 BURLINGTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that on May 8, 2023, it received confirmation from the U.S. Food and Drug Administration (FDA) that the Company's New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia has been filed in accordance with the recent Appeal Granted letter dated April 27, 2023 and assigned a standard review classification.

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023.

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Fred Ahlholm - CFO Conference Call Participants Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Operator Good day, and thank you for standing by.

Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript

Company to Host Conference Call Today at 8:30 a.m. ET Company to Host Conference Call Today at 8:30 a.m. ET

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Management to Host Conference Call Management to Host Conference Call

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Frederick Ahlholm - CFO Conference Call Participants Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Myles Minter - William Blair Operator Thank you for standing by.

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript

Company To Host Live Webcast Today at 8:30 a.m. ET Company To Host Live Webcast Today at 8:30 a.m. ET

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the third quarter of 2022 on Wednesday, November 9, 2022. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates.

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

Greenwich Lifesciences

Aerovate Therapeutics

HeartBeam

Virgin Orbit Holdings

Short-squeeze stocks continue to be a big deal for speculative traders and we're helping them out with a list to keep in mind this week! That list comes from Fintel and its Short Squeeze Leaderboard.

News for Minerva Neurosciences Stock (NERV)